Head & Neck Cancer | Topics

FDA Issues Complete Response Letter to Toripalimab for Advanced Nasopharyngeal Carcinoma
May 03, 2022

Plans to resubmit a biologics license application for toripalimab as treatment of advanced recurrent or metastatic nasopharyngeal carcinoma have been made for midsummer 2022 following receipt of a complete response letter from the FDA.

Upper-Neck Irradiation and Whole-Neck Irradiation Yielded Similar Regional Control in Nasopharyngeal Carcinoma
May 02, 2022

Patients with N0 to N1 nasopharyngeal carcinoma who received upper-neck radiation vs whole-neck radiation saw similar regional control with less radiation toxicity.

Investigators Highlight 4 Themes in Symptom Management for Head and Neck Cancer
May 01, 2022

A qualitative analysis identified 4 themes that could be improved upon to help with symptom management in patients with head and neck cancer.

First-Line Tislelizumab Plus Chemotherapy Could Become SOC in Nasopharyngeal Cancer
April 20, 2022

Investigators of the phase 3 RATIONALE-309 trial found an improvement in progression-free survival for patients with recurrent or metastatic nasopharyngeal cancer treated with tislelizumab plus chemotherapy vs chemotherapy alone.

Positive Responses and Tolerability Reported With Pepinemab Plus Pembrolizumab in Head and Neck Cancer
April 11, 2022

Antitumor activity was noted for patients with recurrent or metastatic head and neck cancer who were treated with pepinemab plus pembrolizumab.

Favorable Outcomes, Improved QOL Seen With Radiotherapy De-Escalation in HPV-Associated Oropharyngeal Carcinoma
April 01, 2022

Patients with human papillomavirus–associated oropharyngeal carcinoma who were given de-escalated doses of radiotherapy saw a better quality of life and favorable outcomes.

Neoadjuvant Chemotherapy May Contribute Towards Mandibular Preservation in Oral Cavity Cancer
March 18, 2022

Investigators believe that neoadjuvant chemotherapy may play a role in mandibular prevention in patients with oral cavity cancer.

Maintenance Capecitabin Yields Significant PFS Improvement in Newly Diagnosed Nasopharyngeal Cancer
March 04, 2022

A significant progression-free survival benefit was observed with the use of capecitabine maintenance therapy in newly diagnosed nasopharyngeal carcinoma vs best supportive care.

Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHN
March 02, 2022

Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.

Tumor-Focused Stereotactic Radiotherapy May be Efficacious in Early Stage Glottic Larynx Carcinoma
February 28, 2022

Patients with early stage glottic larynx carcinoma benefitted from treatment with tumor-focused stereotactic radiotherapy.